Cerebrovascular Accident Associated with Testosterone Therapy in a 21-Year-Old Hypogonadal Man
- 6 March 1986
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 314 (10), 649-650
- https://doi.org/10.1056/nejm198603063141017
Abstract
To the Editor: Men with hypogonadotropic hypogonadism can be virilized by intramuscular administration of a long-acting testosterone ester, such as testosterone enanthate (Delatestryl) or testosterone cypionate (Depo-testosterone). Teaching the patient to self-administer the drug facilitates compliance, and when properly done, such self-administration is an effective and safe mode of therapy.1 Psychosocial pressures, however, may tempt a man to try to hasten his sexual maturation by injecting more than the prescribed dose of testosterone. The potential hazards of supraphysiologic concentrations of circulating testosterone are not known, but the suspicion of an association between overzealous androgen administration and thromboembolic disease was raised . . .Keywords
This publication has 4 references indexed in Scilit:
- The Hypercoagulable StatesAnnals of Internal Medicine, 1985
- Superior sagittal sinus thrombosis associated with androgen therapy for hypoplastic anemiaAnnals of Neurology, 1982
- Testosterone inhibits prostacyclin production by rat aortic smooth muscle cells in cultureAtherosclerosis, 1981
- Treatment of Male Hypogonadism with Testosterone Enanthate*Journal of Clinical Endocrinology & Metabolism, 1980